BSN HESI 315 Pharmacology Practice Exam | New 2026/2027 | Questions & Answers with Detailed Rationales | 100% Correct Grade A | HESI & NCLEX-RN® Pharmacology Review PDF

INSTANT PDF DOWNLOAD — This is the comprehensive Pharmacology Practice Exam preparation guide for BSN HESI 315 (New 2026/2027), featuring questions and answers with detailed rationales. Designed for nursing students preparing for the HESI Pharmacology Exam and NCLEX-RN®, this resource consolidates the essential pharmacology concepts required to achieve a high score on the HESI Pharmacology exam and pass the NCLEX-RN® on the first attempt. The guide is meticulously aligned with HESI testing blueprints, NCLEX-RN® test plan, and current evidence-based pharmacology standards. This verified resource provides comprehensive coverage of key HESI Pharmacology exam topics, including: Pharmacokinetics and Pharmacodynamics (absorption—bioavailability, first-pass effect (oral medications metabolized by liver before reaching systemic circulation, reduced bioavailability, alternative routes (IV, IM, sublingual, rectal) bypass first-pass), factors affecting absorption (route of administration (IV fastest, then IM, subQ, PO, rectal, topical, transdermal), blood flow (increased blood flow increases absorption), pain/stress (decreases gastric emptying, delays absorption), food (affects absorption rate, some meds need empty stomach (levothyroxine, bisphosphonates), some with food (NSAIDs, metformin, prednisone)), pH (acidic drugs absorbed in stomach (aspirin), basic drugs absorbed in small intestine), surface area (small intestine large surface area, most absorption), motility (diarrhea decreases absorption, constipation increases contact time), distribution—volume of distribution (Vd = amount of drug in body / plasma concentration), high Vd (drug distributes to tissues, long half-life, digoxin, amiodarone, chloroquine, hydroxychloroquine, azithromycin, TCAs), low Vd (drug remains in plasma, short half-life, warfarin, aspirin, NSAIDs, many beta-lactam antibiotics), protein binding (highly protein-bound drugs (90%): warfarin (99%), phenytoin (90-95%), digoxin (25-30% low), valproate (90%), ceftriaxone (85-95%), diazepam (99%), furosemide (95%), thyroid hormones (99%), clozapine (95%), haloperidol (92%), only free (unbound) drug is active, drug-drug displacement interactions (two highly protein-bound drugs compete for binding sites, increase free concentration of one or both, risk toxicity (warfarin + phenytoin, warfarin + valproate, warfarin + sulfonamides, warfarin + ceftriaxone, phenytoin + valproate), albumin (decreased in malnutrition, liver disease, nephrotic syndrome, burns, elderly, pregnancy, increases free drug concentration, toxicity risk)), blood-brain barrier (tight junctions in brain capillaries, lipid-soluble drugs cross (benzodiazepines, opioids, general anesthetics, antipsychotics, antidepressants, alcohol, nicotine, caffeine), P-glycoprotein (P-gp) efflux pump (pumps drugs back into blood, limits CNS penetration), inflammation (meningitis, encephalitis, brain tumors, trauma disrupt BBB, increases drug penetration), pregnancy (placental transfer, lipid-soluble, low molecular weight, non-ionized drugs cross easily (opioids, benzodiazepines, anticonvulsants, alcohol, nicotine, cocaine, general anesthetics), teratogenic risk highest in first trimester (organogenesis, days 15-60 post-conception)), metabolism—liver (phase I (CYP450 system: oxidation, reduction, hydrolysis, makes drug more polar, may activate prodrug (codeine→morphine (CYP2D6), clopidogrel→active metabolite (CYP2C19), enalapril→enalaprilat (esterase), losartan→EXP3174 (CYP2C9), tramadol→O-desmethyltramadol (CYP2D6), tamoxifen→endoxifen (CYP2D6, CYP3A4)), CYP450 inducers (increase metabolism, decrease drug levels, reduce efficacy—rifampin (strong), carbamazepine (strong), phenytoin (strong), phenobarbital (strong), St. John's wort (strong), smoking (polycyclic aromatic hydrocarbons induce CYP1A2), glucocorticoids (dexamethasone, prednisone), griseofulvin, modafinil, efavirenz, nevirapine, bosentan, chronic alcohol use (induces CYP2E1)), CYP450 inhibitors (decrease metabolism, increase drug levels, risk toxicity—ketoconazole, itraconazole (strong CYP3A4 inhibitors), clarithromycin, erythromycin (strong CYP3A4 inhibitors), ritonavir, cobicistat (strong CYP3A4 inhibitors), grapefruit juice (CYP3A4 inhibitor in gut, increases levels of statins (simvastatin, atorvastatin, lovastatin), calcium channel blockers (nifedipine, felodipine), cyclosporine, tacrolimus, buspirone, triazolam, midazolam, sildenafil, tadalafil, vardenafil, amiodarone, verapamil, diltiazem, cimetidine (weak inhibitor of multiple CYPs), fluconazole (CYP2C9, CYP2C19, CYP3A4 inhibitor), omeprazole, esomeprazole (CYP2C19 inhibitors), valproate (CYP2C9, CYP2C19, UGT inhibitor), amiodarone (CYP2C9, CYP2C19, CYP2D6, CYP3A4 inhibitor), ciprofloxacin (CYP1A2 inhibitor), fluoxetine, paroxetine, bupropion (CYP2D6 inhibitors)), phase II (conjugation (glucuronidation (UGT)—morphine, acetaminophen, lamotrigine, valproate, propofol, bilirubin, acetylation (N-acetyltransferase—isoniazid, hydralazine, procainamide, dapsone, sulfonamides), sulfation, methylation, glutathione conjugation (acetaminophen detoxification, depleted in overdose → hepatotoxicity)), genetic polymorphisms (CYP2D6 (poor metabolizers: codeine ineffective (cannot convert to morphine), increased toxicity for metoprolol, carvedilol, tramadol, haloperidol, risperidone, venlafaxine (higher levels); ultrarapid metabolizers: codeine toxicity (rapid conversion to morphine, respiratory depression, death, contraindicated in breastfeeding (infant death)), tramadol toxicity, tamoxifen reduced efficacy? no, ultrarapid metabolizers may have increased endoxifen levels, improved outcomes? controversial), CYP2C19 (poor metabolizers: clopidogrel resistance (reduced activation, increased risk stent thrombosis, MI, stroke), increased diazepam, omeprazole, phenytoin levels, dose adjustment; ultrarapid metabolizers: clopidogrel active, no dose adjustment needed, but increased bleeding risk? not established), CYP2C9 (poor metabolizers: warfarin sensitivity (reduce dose, monitor INR), phenytoin toxicity (reduce dose), NSAID toxicity (ibuprofen, naproxen, celecoxib, increased GI bleeding), sulfonylurea hypoglycemia (glipizide, glyburide, glimepiride)), N-acetyltransferase (slow acetylators: isoniazid-induced peripheral neuropathy (give pyridoxine (B6)), hydralazine-induced lupus (positive ANA, arthralgias, rash, pericarditis, pleuritis), procainamide-induced lupus, increased risk), elimination—renal (glomerular filtration (free drug, not protein-bound, small molecular weight), tubular secretion (active transport, organic anion transporters (OAT), organic cation transporters (OCT), affected by probenecid (blocks OAT, increases penicillin, cephalosporin, cidofovir levels), trimethoprim (blocks OCT, increases creatinine (falsely elevated, not true kidney injury), increases procainamide, dofetilide, metformin (rare))), tubular reabsorption (passive diffusion, affected by urine pH (acidic urine promotes reabsorption of weak acids, promotes excretion of weak bases (alkalinize urine to excrete weak acids (salicylate overdose, methotrexate), acidify urine to excrete weak bases (amphetamine, phencyclidine (PCP) overdose, rare)), drug interactions affecting renal elimination (NSAIDs (decrease renal blood flow, decrease lithium, methotrexate, digoxin elimination, increase toxicity), ACE inhibitors/ARBs (decrease GFR, decrease lithium elimination, increase lithium levels), loop/thiazide diuretics (volume depletion, decrease GFR, decrease lithium elimination), trimethoprim (blocks creatinine secretion, falsely elevated Cr, not true AKI, also decreases metformin elimination), cimetidine (decreases creatinine secretion, falsely elevated Cr, decreases procainamide, dofetilide elimination, increases levels), probenecid (blocks OAT, increases penicillin, cephalosporin levels, used to increase antibiotic levels in treating resistant infections (gonorrhea, syphilis, UTI)), half-life (time for drug concentration to decrease by 50%, determines dosing interval (drugs with short half-life (minutes to hours): IV anesthetics